Renaissance Capital logo

Tevogen Bio (Semper Paratus Acquisition) Priced, Nasdaq: TVGN

Blank check company led by the former CFO of UPS targeting transportation, supply chain, and logistics (completed 2/14/2024).

Industry: SPAC

Latest Trade: $1.00 0.00 (0.0%)

First Day Return: +0.8%

Return from IPO: -90.0%

Industry: SPAC

Semper Paratus Acquisition Corporation (“Semper Paratus”) is a newly organized, special purpose acquisition company. While we may pursue an initial business combination with a company in any business, industry, sector or geographic location, we currently intend to concentrate our efforts to pursue an acquisition opportunity in the transportation, supply chain and logistics industry in any stage of the target’s corporate evolution. Traditional and next-generation supply chain solutions, physical or digital, are driving essential changes across end markets as business leaders around the world navigate unprecedented supply chain disruption caused by the COVID-19 pandemic. Our management team is led by Richard N. Peretz, our Executive Chairman, Hooman Yazhari, our Vice Chairman, Ben Baldanza, our Chief Executive Officer, Jeff Rogers, our President, and Philippe J. Kurzweil, our Chief Financial Officer. Richard N. Peretz serves as Executive Chairman. From 1981 to 2019, Mr. Peretz held a number of executive roles at United Parcel Service, Inc. (“UPS”) in US and Global operations as well as in Supply Chain Management. From 2015 to 2019, he served as Chief Financial Officer (CFO) and a member of the UPS Executive Leadership Team.
more less
IPO Data
IPO File Date 10/07/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 30.0
Deal Size ($mm) $300
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/03/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 30.0
Deal Size ($mm) $300
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Cantor Fitzgerald
Company Data
Headquarters New York, NY, United States
Founded 2021
Employees 3

Tevogen Bio (Semper Paratus Acquisition) (TVGN) Performance